Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

October 29, 2024

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

News Conference News TCT 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

October 24, 2023

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

News Conference News

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

November 18, 2022

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

News Conference News TCT 2022

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

September 21, 2022

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

October 12, 2021

More Real-world Data Support Safety of Paclitaxel-Based Devices in PAD

News Conference News VEITH 2019

More Real-world Data Support Safety of Paclitaxel-Based Devices in PAD

November 22, 2019

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

News Conference News VIVA 2019

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

November 05, 2019

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

News Conference News TCT 2019

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

September 28, 2019

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

News Conference News VIVA 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

November 13, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.